About Indoco Remedies Limited

Indoco Remedies Limited is an Indian pharmaceutical company incorporated in 1947, headquartered in Mumbai, and engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) for domestic and international markets. The company operates 9 manufacturing plants and 4 offices across India, serving all States and exporting to 37 countries. Its portfolio spans prescription brands across key therapy areas such as stomatologicals, anti-infectives, gastrointestinal, respiratory, urology, ophthalmology/otology, dermatology and nutraceuticals, with 38 products ranking among the top 5 in their respective sub-segments in India. Complementing its formulations and API businesses, the company also offers analytical research and bio-equivalence services through Indoco Analytical Solutions and its CRO operations; a new state-of-the-art Analytical Services wing at Waluj, India supports stability studies, regulatory submissions and product quality validation under GMP/GLP practices. Indoco has five subsidiaries and two associates, reflecting a growing international footprint across the UK, Europe and the US.

Key Milestones of Indoco Remedies Limited

Key milestones include seven-plus decades of operations—Indoco marked “77 years of excellence” during Foundation Day 2024—alongside steady expansion of therapeutic coverage and manufacturing capacity across its Indian sites.

Indoco Remedies Limited Business Verticals and Geographical Presence 

Segment/vertical contribution to revenue:

• Domestic Formulations: 43%
• Export Formulations: 48%
• API: 9%

Exports as share of standalone revenue: 38.70%

Indoco operates 9 manufacturing plants and 4 offices across India, serving all States and exporting to 37 countries. The company has five subsidiaries and two associates, reflecting a growing international footprint across the UK, Europe and the US.

Indoco Remedies Limited Business Segment

Indoco manufactures and markets pharmaceutical formulations and APIs and also provides analytical research and bio-equivalence services. Revenue contribution by segment/vertical is Domestic Formulations 43%, Export Formulations 48% and API 9%. The company operates 9 plants and 4 offices in India and serves all States, exporting to 37 countries. On a standalone basis, exports contributed 38.70% of revenue in FY 2024-25.

Indoco Remedies Limited Key Management

• Suresh G Kare – Chairman
• Aditi Panandikar – Managing Director
• Sundeep V Bambolkar – Joint Managing Director
• Pramod Ghorpade – Chief Financial Officer
• Ramanathan Hariharan – Company Secretary & Head – Legal

Latest Updates on Indoco Remedies Limited

• Strategic distribution partnership in the UK: Indoco entered a UK distribution tie-up with Clarity Pharma, under which it plans launches over eighteen months to strengthen its presence in that market.
• Product launches in the UK: First-day launch of Ticagrelor film-coated tablets in the United Kingdom through Indoco Remedies UK Limited.
• US approvals and designations: Lofexidine Tablets 0.18 mg received Competitive Generic Therapy designation in the US; Varenicline Tablets (0.5 mg/1 mg) were launched in the US; additionally, Lofexidine tablets and Lacosamide tablets and injections were launched on Day One in the US market during the year.
• New division and therapy expansion in India: Launch of “Indoco Insta”, a new Corporate Hospital division; the company also entered two high-potential therapy segments—dermatologicals and anti-glaucoma—while continuing leadership in established areas. Kashmir was newly integrated into Indoco’s marketing territories in India.
• Manufacturing and capacity initiatives: A Master Manufacturing Plan was implemented across most facilities to drive larger batch sizes, automation and cost rationalisation, with capacities augmented in four large Solid Oral Plants during FY 2024-25.
• R&D and analytical capabilities: Inauguration of a state-of-the-art Analytical Services wing at Waluj under Indoco Analytical Solutions to support ICH-compliant stability testing and dossier submissions (CTD/ANDA/NDA).
• Brand performance recognition: 38 brands ranked among the top 5 in their sub-segments in India, highlighting strong market positioning across multiple therapies.